Could daratumumab be used to treat severe allergy? - 27/09/17
Doi : 10.1016/j.jaci.2016.12.955
Mark A. Blankestijn, MD a 
, Niels W.C.J. van de Donk, MD, PhD b, Kate Sasser, PhD c, André C. Knulst, MD, PhD a, Henny G. Otten, PhD d
, Niels W.C.J. van de Donk, MD, PhD b, Kate Sasser, PhD c, André C. Knulst, MD, PhD a, Henny G. Otten, PhD d a Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands
b Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
c Janssen Research & Development, Spring House, Pa
d Department of Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
| Disclosure of potential conflict of interest: M. A. Blankestijn's institution has received payment for lectures from ThermoFisher Scientific. N. W. C. J. van de Donk's institution has received grants from Celgene, Janssen, Amgen, and BMS for other works; has personally received payment for lectures from Celgene, Janssen, Amgen, and BMS. K. Sasser is employed by Janssen PRD. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2017
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 139 - N° 5
P. 1677 - mai 2017 Retour au numéro
Article précédent
- IFN-? orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of rapamycin pathways
- Tiziana Vigo, Claudio Procaccini, Giovanni Ferrara, Sergio Baranzini, Jorge R. Oksenberg, Giuseppe Matarese, Alberto Diaspro, Nicole Kerlero de Rosbo, Antonio Uccelli
- Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials
- Carlos Iribarren, Kenneth J. Rothman, Mary S. Bradley, Gillis Carrigan, Mark D. Eisner, Hubert Chen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?